Drugs / Lonquek
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02488382 | Jul 2017 → Jul 2018 | plasma cell myeloma | Sheba Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lonquek | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02488382 ↗ |
| Modality | Protein / enzyme biologic | “Lonquek which is a pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF)” NCT02488382 ↗ |
| Route | Subcutaneous | “12-mg subcutaneously” NCT02488382 ↗ |